Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-06 23:03 | 2025-06-05 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Officer | SELL | $13.35 | 146 | $1,949 | 95,911 |
| 2025-06-06 23:05 | 2025-06-05 | DYN | Dyne Therapeutics, Inc. | Kerr Douglas | Officer | SELL | $13.35 | 1,342 | $17,916 | 92,815 |
| 2025-06-07 01:05 | 2025-06-04 | VREO | Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% owner | BUY | $0.41 | 26,000 | $10,530 | 32,906,868 |
| 2025-06-07 01:04 | 2025-06-06 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | Officer | SELL | $6.76 | 17,795 | $120,294 | 491,246 |
| 2025-06-07 00:49 | 2025-06-04 | ROIV | Roivant Sciences Ltd. | Ramaswamy Vivek | 10% owner | SELL | $11.30 | 748,230 | $8,454,775 | 38,426,381 |
| 2025-06-06 23:20 | 2025-06-04 | STOK | Stoke Therapeutics, Inc. | Skorpios Trust | 10% owner | SELL | $10.20 | 3,000,000 | $30,600,000 | 3,906,181 |
| 2025-06-07 00:00 | 2025-06-04 | ASBP | Aspire Biopharma Holdings Inc. | Fell Donald G. | Director | BUY | $0.39 | 20,000 | $7,800 | 20,000 |
| 2025-06-07 00:58 | 2025-06-05 | XENE | Xenon Pharmaceuticals Inc. | GANNON STEVEN | Director | SELL | $30.48 | 3 | $91 | 7,141 |
| 2025-06-06 23:07 | 2025-06-05 | DYN | Dyne Therapeutics, Inc. | Cox John | Director, Officer | SELL | $13.35 | 4,060 | $54,201 | 142,179 |
| 2025-06-07 00:44 | 2025-06-04 | ORGO | Organogenesis Holdings Inc. | Freedman Lori | Officer | BUY | $2.88 | 252,264 | $725,284 | 846,459 |
| 2025-06-06 15:44 | 2025-06-04 | ARQT | Arcutis Biotherapeutics Inc. | Heron Patrick J | Director | BUY | $13.34 | 2,268 | $30,247 | 24,802 |
| 2025-06-06 23:43 | 2025-06-04 | TYRA | Tyra Biosciences, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | BUY | $9.70 | 1,211,198 | $11,751,285 | 9,909,154 |
| 2025-06-07 00:00 | 2025-06-04 | IMUX | IMMUNIC, INC. | Vitt Daniel | Director, Officer | BUY | $0.77 | 15,000 | $11,550 | 29,000 |
| 2025-06-06 23:53 | 2025-06-05 | INSM | INSMED Inc | Smith Michael Alexander | Officer | SELL | $73.50 | 1,879 | $138,107 | 67,718 |
| 2025-06-06 15:39 | 2025-05-01 | CPIX | CUMBERLAND PHARMACEUTICALS INC | Krogulski Kenneth | Director | BUY | $5.11 | 945 | $4,824 | 285,698 |
| 2025-06-06 15:38 | 2025-05-01 | CPIX | CUMBERLAND PHARMACEUTICALS INC | Jones James | Director | BUY | $5.11 | 168 | $858 | 43,168 |
| 2025-06-06 15:37 | 2025-05-01 | CPIX | CUMBERLAND PHARMACEUTICALS INC | Young Caroline | Director | BUY | $5.11 | 84 | $429 | 32,569 |
| 2025-06-06 15:36 | 2025-05-01 | CPIX | CUMBERLAND PHARMACEUTICALS INC | KAZIMI A J | Director, Officer, 10% owner | BUY | $5.11 | 168 | $858 | 5,699,260 |
| 2025-06-06 00:08 | 2025-06-03 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Shields Matthew | Officer | OPT+S | $17.02 | 6,206 | $105,628 | 9,989 |
| 2025-06-06 03:53 | 2025-06-03 | SXTP | 60 DEGREES PHARMACEUTICALS, INC. | XU CHERYL | Director | BUY | $2.88 | 5,000 | $14,410 | 15,816 |
| 2025-06-05 23:42 | 2025-06-03 | MAIA | MAIA Biotechnology, Inc. | Smith Stan | Director | BUY | $1.50 | 33,333 | $50,000 | 1,305,059 |
| 2025-06-05 23:20 | 2025-06-04 | LQDA | Liquidia Corp | Schundler Russell | Officer | OPT+S | $16.97 | 8,460 | $143,566 | 582,054 |
| 2025-06-05 23:19 | 2025-06-04 | LQDA | Liquidia Corp | Saggar Rajeev | Officer | OPT+S | $16.97 | 7,597 | $128,921 | 273,209 |
| 2025-06-05 23:20 | 2025-06-04 | LQDA | Liquidia Corp | Moomaw Scott | Officer | OPT+S | $16.97 | 6,656 | $112,952 | 224,921 |
| 2025-06-05 23:15 | 2025-06-04 | LQDA | Liquidia Corp | Adair Jason | Officer | OPT+S | $16.97 | 3,597 | $61,041 | 193,735 |
| 2025-06-05 23:46 | 2025-06-03 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Officer | OPT+S | $29.02 | 27,594 | $800,778 | 9,415 |
| 2025-06-05 23:38 | 2025-06-03 | KNSA | Kiniksa Pharmaceuticals International, plc | Ragosa Mark | Officer | OPT+S | $28.80 | 18,299 | $527,011 | 27,009 |
| 2025-06-05 23:18 | 2025-06-04 | LQDA | Liquidia Corp | Kaseta Michael | Officer | OPT+S | $16.97 | 14,777 | $250,766 | 412,164 |
| 2025-06-05 23:55 | 2025-06-03 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $20.03 | 7,500 | $150,220 | 977,688 |
| 2025-06-05 23:53 | 2025-06-03 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Director, Officer | SELL | $20.05 | 7,500 | $150,352 | 965,392 |
| 2025-06-06 00:15 | 2025-06-03 | ETON | Eton Pharmaceuticals, Inc. | BRYNJELSEN SEAN | Director, Officer, 10% owner | SELL | $17.11 | 210,000 | $3,592,617 | 2,873,513 |
| 2025-06-05 23:35 | 2025-06-04 | AKBA | Akebia Therapeutics Inc. | Malabre Richard C | Officer | SELL | $3.53 | 13,334 | $47,069 | 266,914 |
| 2025-06-05 23:50 | 2025-06-03 | KNSA | Kiniksa Pharmaceuticals International, plc | Megna Michael R | Officer | OPT+S | $28.75 | 15,211 | $437,316 | 32,546 |
| 2025-06-06 00:40 | 2025-06-04 | PCRX | Pacira BioSciences, Inc. | RIKER LAUREN | Officer | SELL | $26.21 | 5,578 | $146,208 | 59,564 |
| 2025-06-05 23:16 | 2025-06-03 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Meeker David P | Director, Officer | OPT+S | $65.05 | 43,620 | $2,837,333 | 201,825 |
| 2025-06-05 23:05 | 2025-06-03 | HROW | HARROW, INC. | Opaleye Management Inc. | 10% owner | SELL | $30.03 | 4,796 | $144,023 | 120,204 |
| 2025-06-06 00:37 | 2025-06-04 | PCRX | Pacira BioSciences, Inc. | WILLIAMS KRISTEN | Officer | SELL | $26.24 | 14,376 | $377,226 | 161,574 |
| 2025-06-05 23:07 | 2025-06-04 | IMUX | IMMUNIC, INC. | Neermann Joerg | Director | BUY | $0.77 | 100,000 | $76,700 | 200,000 |
| 2025-06-05 23:18 | 2025-06-04 | LQDA | Liquidia Corp | JEFFS ROGER | Director, Officer | OPT+S | $16.97 | 30,610 | $519,452 | 1,044,979 |
| 2025-06-05 23:16 | 2025-06-03 | RYTM | RHYTHM PHARMACEUTICALS, INC. | MCGIRR DAVID W J | Director | OPT+S | $65.22 | 65,431 | $4,267,495 | 3,000 |
| 2025-06-05 16:11 | 2025-06-04 | ANIX | Anixa Biosciences Inc. | KUMAR AMIT | Officer | BUY | $2.85 | 10,000 | $28,500 | 569,925 |
| 2025-06-06 01:01 | 2025-06-04 | ACAD | Acadia Pharmaceuticals Inc. | Brege Laura | Director | SELL | $21.78 | 14,446 | $314,634 | 15,095 |
| 2025-06-05 23:42 | 2025-06-05 | CYTK | CYTOKINETICS INC | Kaye Edward M. MD | Director | SELL | $32.10 | 3,636 | $116,716 | 29,658 |
| 2025-06-05 23:38 | 2025-06-05 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | SELL | $32.04 | 8,659 | $277,434 | 52,028 |
| 2025-06-04 23:05 | 2025-06-02 | VREO | Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% owner | BUY | $0.40 | 182,700 | $72,970 | 32,880,868 |
| 2025-06-05 00:36 | 2025-06-02 | AKRO | Akero Therapeutics, Inc. | Lamy Patrick | Officer | OPT+S | $50.31 | 4,000 | $201,258 | 33,492 |
| 2025-06-04 23:34 | 2025-06-02 | ZLAB | Zai Lab Ltd | Chen Yajing | Officer | SELL | $30.00 | 9,618 | $288,540 | 17,429 |
| 2025-06-05 04:00 | 2025-06-02 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $11.15 | 1,000,000 | $11,154,900 | 1,462,223 |
| 2025-06-05 03:30 | 2025-06-02 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer | SELL | $10.02 | 8,216 | $82,342 | 25,782 |
| 2025-06-04 23:48 | 2025-06-02 | RNA | Avidity Biosciences, Inc. | Gallagher Kathleen P. | Officer | OPT+S | $32.48 | 5,875 | $190,833 | 50,554 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.